Chronic lymphocytic leukemia (CLL) is a B-cell malignancy, with disease progression ranging from slow and indolent to ...

Research found that ibrutinib reduces red blood cell aggregation in patients with chronic lymphocytic leukemia (CLL), while ...

The molecular mechanisms underlying resistance to therapy in Chronic lymphocytic leukemia (CLL) remain to be explored. Here, the authors perform multi-omics analysis in a mouse model of ibrutinib ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK ...

Treatment for CLL continues to change. Doctors are using newer targeted cancer drugs. This means a stem cell transplant is now a less common treatment for CLL. You have a transplant using donor cells ...

A Cownose stingray at the Flordia Aquarium is being recognized as a part of the nationwide World Cancer Day celebration on ...

Healthcare providers in the United States typically use the Rai system to stage chronic lymphocytic leukemia (CLL). This system is based on the number of lymphocytes (white blood cells ...

preventing the body from producing the normal blood cells and platelets it needs. CML originates from a genetic abnormality called the Philadelphia chromosome. It is also known as chronic granulocytic ...

B-cell prolymphocytic leukemia (B-PLL) is a rare, aggressive type of leukemia that progresses rapidly. People with B-PLL typically have a less favorable outlook. However, new targeted treatments ...

MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...

Malignant, immature white blood cells continuously multiply and ... to differentiate it from the very different disease of chronic lymphocytic leukemia, which has a potential time course of ...

Patients with chronic lymphocytic leukemia are at increased risk of developing PML owing to underlying immunocompromise ... Risk factors for PML include immunosuppression, including HIV, hematologic ...